Omeros (NASDAQ:OMER) Raised to Hold at StockNews.com

Omeros (NASDAQ:OMER) was upgraded by stock analysts at StockNews.com from a “sell” rating to a “hold” rating in a note issued to investors on Thursday.

Several other equities analysts have also recently commented on the stock. Rodman & Renshaw started coverage on shares of Omeros in a research report on Thursday, November 14th. They set a “buy” rating and a $9.00 price target on the stock. Needham & Company LLC reissued a “hold” rating on shares of Omeros in a report on Friday, January 17th. Cantor Fitzgerald reissued a “neutral” rating on shares of Omeros in a report on Thursday, November 14th. RODMAN&RENSHAW raised shares of Omeros to a “strong-buy” rating in a report on Thursday, November 14th. Finally, D. Boral Capital reissued a “buy” rating and issued a $36.00 target price on shares of Omeros in a report on Thursday, February 20th. Three analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Omeros presently has an average rating of “Moderate Buy” and an average target price of $22.50.

Omeros Stock Performance

Shares of OMER stock opened at $8.42 on Thursday. Omeros has a one year low of $2.61 and a one year high of $13.60. The company’s 50-day simple moving average is $8.80 and its 200-day simple moving average is $7.15. The stock has a market capitalization of $487.94 million, a price-to-earnings ratio of -3.65 and a beta of 2.03.

Institutional Investors Weigh In On Omeros

Several large investors have recently made changes to their positions in OMER. Nomura Holdings Inc. increased its stake in shares of Omeros by 136.2% in the fourth quarter. Nomura Holdings Inc. now owns 747,281 shares of the biopharmaceutical company’s stock valued at $7,383,000 after purchasing an additional 430,932 shares during the period. Susquehanna Fundamental Investments LLC acquired a new position in shares of Omeros during the fourth quarter valued at approximately $1,488,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Omeros during the fourth quarter valued at approximately $1,120,000. Jacobs Levy Equity Management Inc. acquired a new position in shares of Omeros during the fourth quarter valued at approximately $1,033,000. Finally, Ancora Advisors LLC grew its position in Omeros by 1,036.4% in the fourth quarter. Ancora Advisors LLC now owns 85,800 shares of the biopharmaceutical company’s stock worth $848,000 after buying an additional 78,250 shares during the last quarter. Institutional investors and hedge funds own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.